224 related articles for article (PubMed ID: 11640994)
1. Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomised multinational study.
Tamás G; Marre M; Astorga R; Dedov I; Jacobsen J; Lindholm A;
Diabetes Res Clin Pract; 2001 Nov; 54(2):105-14. PubMed ID: 11640994
[TBL] [Abstract][Full Text] [Related]
2. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
Home PD; Lindholm A; Riis A;
Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D
Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130
[TBL] [Abstract][Full Text] [Related]
5. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
7. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women.
Mathiesen ER; Kinsley B; Amiel SA; Heller S; McCance D; Duran S; Bellaire S; Raben A;
Diabetes Care; 2007 Apr; 30(4):771-6. PubMed ID: 17392539
[TBL] [Abstract][Full Text] [Related]
8. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
Raskin P; Guthrie RA; Leiter L; Riis A; Jovanovic L
Diabetes Care; 2000 May; 23(5):583-8. PubMed ID: 10834413
[TBL] [Abstract][Full Text] [Related]
9. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
[TBL] [Abstract][Full Text] [Related]
10. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
[TBL] [Abstract][Full Text] [Related]
11. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial.
Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T
Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415
[TBL] [Abstract][Full Text] [Related]
13. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
[TBL] [Abstract][Full Text] [Related]
14. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes.
Chen JW; Lauritzen T; Bojesen A; Christiansen JS
Diabetes Obes Metab; 2006 Nov; 8(6):682-9. PubMed ID: 17026493
[TBL] [Abstract][Full Text] [Related]
15. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
[TBL] [Abstract][Full Text] [Related]
16. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
[TBL] [Abstract][Full Text] [Related]
17. Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.
Banerjee S; Maji D; Baruah M
J Assoc Physicians India; 2013 Jan; 61(1 Suppl):24-7. PubMed ID: 24482984
[TBL] [Abstract][Full Text] [Related]
18. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
19. Multicenter, open-label, nonrandomized, observational safety study in subjects using insulin aspart in basal-bolus regimen for the treatment of diabetes.
Krzymień J; Kobli T; Nazar M
Pol Arch Med Wewn; 2010 Nov; 120(11):444-50. PubMed ID: 21102380
[TBL] [Abstract][Full Text] [Related]
20. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]